Index
lymphomas
(C o n tin u e d )
effusions, 566-568
eye, 466-467
follicular, 30
karyotyping, 26
kidney cancer, 844
Langerhans cell histiocytosis, 703-704
large cell
see
ALCL (anaplastic large cell
lymphoma); DLBCL (diffuse large
B-cell lymphoma)
low-grade follicular (Grades 1 and 2),
686-687
lymphocitic, 531
lymphoplasmacytic, 33, 692-694
MALT
see
MALT (mucosa-associated
lym phoid tissue) lymphoma
mantle cell, 30-31, 694-695
marginal zone B-cell, 30, 31-33,
689-690
polymorphic B-cell, 963
precursor lymphoblastic, 700, 791
primary genital tract, 267
primary mediastinal large B-cell,
791-794
retroperitoneum, 862
small cell,
5 6 7
small lymphocytic, 30, 33, 690-692
small or small and medium-sized
cells, 686
stomach, 391-392
T-cell, 698-699
thyroid gland, 658-659,
6 6 0
translocation detection, 1081
transplant immunosuppressive therapy,
963-964
uterus, 266
Waldenstrom macroglobulinemia,
692-694
lymphoplasmacytic lymphoma (LPL), 33,
692-694
lymphoproliferative disorders, transplant
immunosuppressive therapy, 963
lysing fixation, bloddy samples, 979-980
lysosomes, 8
M
mABs (monoclonal antibodies), chain-specific,
197
macrogenerative nodule, liver, 885
macrohematuria, renal allograft
monitoring, 432
macrophages
effusions, 532-533
eyelids, 458
hemosiderin-laden, CNS, 443
lungs, 308
and red blood cells, 529
tingle body, mediastinum, 777
urinary tract, 432
macrophages, lung, 316
Maffucci syndrome, angiosarcoma, 485
magnetic resonance imaging
(MRI), 601
MAI (mycobacterium avium), 321, 396
malacoplakia
cervix, 100
urinary tract, 416
vagina, 279
maligant mixed tumor, salivary glands, 622
malignant fibrous histiocytoma (MFH)
see
MFH (malignant fibrous histiocytoma)
malignant melanoma
in children, 937
effusions, 570
immunocytochemistry, 1065-1066
metastasis to brain, 446-447
uterine body and cervix, 267
vagina, 283
malignant methothelioma, 1079-1080
MALT (mucosa-associated lym phoid tissue)
lymphoma, 31, 32, 675
stomach, 391
mammography, 715-716
mantle cell lymphomas (MCL)
see
MCL
(mantle cell lymphomas)
marginal zone B-cell lymphomas, 30, 31-33,
689-690
FISH strategy, 41
markers
adenocarcinoma, 1053-1054
lineage-associated, 672-673
mesothelial
see
mesothelial markers
site-specific, 1054-1055
tum or
see
tum or markers
mast cells, 531-532
mastitis, 718,
719
matrix-metallo-proteinases (MMPs), 13
maxillary tumors, children, 917
May-Grunwald Giemsa (modified) stain
oncocytoma (oxyphillic adenomas),
salivary gland, 616
salivary glands, 607, 618
technique, 592
thyroid gland, 635, 641
Mayo Clinic Lung Project, 334-335
MCL (mantle cell lymphomas), 30-31,
694-695
A T M
(ataxia-telangiectasia) gene, 31
blastoid variant, 701
clinical, 694
C yclin D 1
gene, 31
cytomorphology, 694
differential diagnosis, 694-695
karyotyping, 31
MCM (m ini chromosome maintenance), 239
MD Anderson Cancer Center Group,
on breast cancer, 714
M D M 2
gene amplification, sarcomas, 37-38
mediastinum
acute mediastinitis, 777
algorithims, diagnostic
large-cell rich, 802-803
small-cell rich lesions, 802
spindle cell-rich, 803-804
anaplastic large-cell lymphoma,
794-795
anatomic compartments, clinical
correlation, 773
Castleman's disease, 778-779
chronic scleroising mediastinitis, 777
cysts, benign, 776
diagnostic pitfalls, 802
embryonal carcinoma, 786, 788
extramedullary hematopoiesis, 779
fine needle aspiration biopsy,
773-774,
7 7 5
image-guided, 605
mediastinum
(C o n tin u e d )
follicular dendritic cell sarcoma, 799
granulomatous lymphadenitis, 777-778
hyperplasia, 776-777
large B-cell lymphoma, primary
mediastinal, 791-794
lipomas, 798
liposarcoma, 798
metastatic disease, 800-801
neoplastic lesions, 779-801
neurilemmoma, 796
neurofibroma, 796
nodular hyperplasia, thyroid gland, 778
non-neoplastic lesions, 776-779
paraganglioma, 798
parathyroid adenoma, 799-800
pediatric disorders, 923-924
precursor T-lymphoblastic
lymphoma, 791
reactive lymphoid hyperplasia,
776-777
reactive mesothelial hyperplasia, 776
semionoma, 785-786,
7 8 7
soft tissue tumors, 798-799
spindle cells, 796
technical considerations of
therapy, 774
teratoma, 790-791
thymic carcinoma, 783-784
thymic neuroendocrine tumors,
784-785
thymoma, 779-783
yolk sac tumor, 788-789
medulla, tumors o f
ganglioneuroblastoma, 856-857
ganglioneuroma, 856-857
neuroblastomas, 856-857
pheochromocytomas, 853-856
medullary carcinoma
breast, 737-739,
7 42, 743
in children, 919,
9 2 0 ,
945-946
thyroid gland, 654-655,
6 5 6
medulloblastomas, central nervous system,
447, 448
megakaryocytes, 534
meiosis, 24-25
Melamed-Wolinska bodies, urothelial
carcinoma, 555
melanocytic tumors, eyelids, 458
melanomas
"balloon cell", 556
Breslow's level, 279
Clark's level, 279
effusions, 555-557
epithelial-type, 465
malignant
see
malignant melanoma
nodular, in children,
9 3 6
ocular, 464-466, 467
vagina,
2 8 4
vulva, 279
melanotic neuroectodermal tum or o f infancy,
941-942
Memorial Sloan Kettering Cancer Center,
narrow-guage needle sampling by, 579
MEN (m ultiple endocrine neoplasia)
syndrome, 654
menarche, and vaginal microbiology, 91
M ENII (m ultiple endocrine neoplasia II), 13
meningeal carcinomatosis, 447
1109
previous page 1092 ComprehensiveCytopathology 1104p 2008 read online next page 1094 ComprehensiveCytopathology 1104p 2008 read online Home Toggle text on/off